InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.225

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$135 Paradigm CEO Paul Rennie to transition to Non-Exec Chairman 22 Nov 2021 8:46AM $2.150 $0.225 fallen by 89.53%
$135 Paradigm welcomes Dr Reiter from bene pharmaChem to the team 18 Nov 2021 8:22AM $2.250 $0.225 fallen by 90%
$135 NOTICE OF RELEASE OF ESCROWED SECURITIES 11 Nov 2021 4:18PM $2.310 $0.225 fallen by 90.26%
$135 Paradigm Presentation to Bell Potter Healthcare Conference 9 Nov 2021 9:28AM $2.310 $0.225 fallen by 90.26%
$135 Global Market Research indicates price for Zilosu 8 Nov 2021 8:59AM $2.390 $0.225 fallen by 90.59%
$135 PARADIGM CLEARED FOR PHASE 3 TRIAL BY US FDA 3 Nov 2021 8:45AM $2.060 $0.225 fallen by 89.08%
$135 Trading Halt 1 Nov 2021 8:38AM $2.060 $0.225 fallen by 89.08%
$135 Date of Annual General Meeting 29 Oct 2021 8:32AM $1.955 $0.225 fallen by 88.49%
$135 Quarterly Update and Appendix 4C - quarterly 28 Oct 2021 8:53AM $1.885 $0.225 fallen by 88.06%
$135 Phase 2 Synovial Fluid Biomarker Study Update 26 Oct 2021 9:21AM $1.895 $0.225 fallen by 88.13%
$135 POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS 13 Oct 2021 8:29AM $1.870 $0.225 fallen by 87.97%
$135 FIRST MPS-VI PATIENT DOSED UNDER PHASE 2 TRIAL IN BRAZIL 30 Sep 2021 10:34AM $2.170 $0.225 fallen by 89.63%
$135 PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION 27 Sep 2021 8:23AM $2.100 $0.225 fallen by 89.29%
$135 AUS ETHICS APPROVAL RECEIVED FOR PHASE 3 TRIAL 24 Sep 2021 8:31AM $2.050 $0.225 fallen by 89.02%
$135 Cleansing Notice 17 Sep 2021 4:33PM $1.820 $0.225 fallen by 87.64%
$135 Notification regarding unquoted securities - PAR 17 Sep 2021 4:30PM $1.820 $0.225 fallen by 87.64%
$135 CHIKV study data published in Peer-Reviewed Journal 13 Sep 2021 8:22AM $1.930 $0.225 fallen by 88.34%
$135 Appendix 4G and 2021 Corporate Governance Statement 27 Aug 2021 8:34AM $1.965 $0.225 fallen by 88.55%
$135 2021 Annual Report and Appendix 4E 27 Aug 2021 8:33AM $1.965 $0.225 fallen by 88.55%
$135 PARADIGM REPORTS IND APPLICATION UPDATE 3 Aug 2021 8:55AM $2.220 $0.225 fallen by 89.86%
$135 Trading Halt 30 Jul 2021 8:55AM $2.220 $0.225 fallen by 89.86%
$135 Quarterly Update and Appendix 4C - quarterly 29 Jul 2021 8:58AM $2.030 $0.225 fallen by 88.92%
$135 Application for quotation of securities - PAR 19 Jul 2021 9:35AM $1.970 $0.225 fallen by 88.58%
$135 Notification of cessation of securities - PAR 14 Jul 2021 6:00PM $1.980 $0.225 fallen by 88.64%
$135 NOTICE OF RELEASE OF ESCROWED SECURITIES 9 Jul 2021 6:17PM $2.020 $0.225 fallen by 88.86%

351 - 375 of 722 results

Page 15 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.